Increased expressions of GLUT1 and GLUT3 are also linked with worse clinical outcomes in patients with glioblastoma and colorectal carcinoma (Cosset et al., 2017, Dai et al., 2020). The gene discussed is SLC2A3; the disease is glioblastoma.